Last reviewed · How we verify
LYMPHIR — Competitive Intelligence Brief
marketed
CD25-directed Cytotoxin [EPC]
Other
Live · refreshed every 30 min
Target snapshot
LYMPHIR (DENILEUKIN DIFTITOX-CXDL) — CITIUS PHARMS.
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LYMPHIR TARGET | DENILEUKIN DIFTITOX-CXDL | CITIUS PHARMS | marketed | CD25-directed Cytotoxin [EPC] | ||
| Ontak | DENILEUKIN DIFTITOX | Eisai | marketed | CD25-directed Cytotoxin [EPC] | Interleukin-2 receptor | 1999-01-01 |
| Ontak | E7777 | Eisai | marketed | CD25-directed Cytotoxin | Interleukin-2 receptor | 1999-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (CD25-directed Cytotoxin [EPC] class)
- CITIUS PHARMS · 1 drug in this class
- Eisai · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LYMPHIR CI watch — RSS
- LYMPHIR CI watch — Atom
- LYMPHIR CI watch — JSON
- LYMPHIR alone — RSS
- Whole CD25-directed Cytotoxin [EPC] class — RSS
Cite this brief
Drug Landscape (2026). LYMPHIR — Competitive Intelligence Brief. https://druglandscape.com/ci/denileukin-diftitox-cxdl. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing